A
lzheimer's disease (AD), the major cause of adult-onset dementia, is characterized by progressive memory loss and severe cognitive decline that are associated with cerebral deposition of b-amyloid (Ab) peptides. Familial, autosomal dominant AD (FAD) is caused by expression of mutant variants of Ab precursor proteins (APP) and presenilins (PS), and expression of these mutant genes in mice leads to cerebral deposition of Ab peptides (1). Cramer et al. (2) reported that bexarotene (Targretin), a retinoid X receptor (RXR) agonist approved by the U.S. Food and Drug Administration (FDA), rapidly reduces Ab levels in the interstitial fluid, reduces amyloid plaque burden, and rescues behavioral deficits in transgenic mouse models of Ab amyloidosis. For example, 6-month-old mice expressing FAD-linked APPswe and PS1∆E9 polypeptides [APP/PS1 mice (3) ] that received daily oral doses of Targretin exhibited a reduction of Ab plaques by~75% within 7 days and significantly reduced levels of soluble and insoluble Ab peptides that accompanied increases in brain levels of apoE, ABCA1, ABCG1, encoded by RXR-target genes, and elevated levels of high- In view of the important implications of these findings for the development of novel AD therapeutics, we have attempted to replicate these findings. We noted that Cramer et al. (2) used a limited number of mice (N = 5 for APP/PS1 mice), and of mixed gender, the latter a confound in the author's interpretation of results, because female APP/PS1 mice exhibit accelerated amyloid deposition, elevated Ab deposition, and elevated amyloid burden, particularly at 6 months of age, compared with their male counterparts (5) .
We performed studies on three mouse models of Ab amyloidogenesis. In the first, cohorts of 6-month-old male APP/PS1 mice (3) [the same strain used by Cramer et al. (2) ], were treated orally with 100 mg per kg of weight (mg/kg) of Targretin or vehicle (6.6% dimethyl sulfoxide; 4% ethanol; 89.6% sunflower oil) for seven consecutive days. Fixed hemibrains were sectioned and stained with 3D6, an Ab N-terminal-specific antibody (6), and bound primary antibodies were visualized using fluorescently labeled secondary antibodies; representative images from individual animals treated with vehicle or Targretin are shown in Fig. 1 , A and D, respectively. Colabeling studies with 3D6 and microglia-specific Iba1 antibodies revealed that Ab was abundantly present within microglia that surrounded plaques in both vehicle- (Fig. 1, B and C) and Targretintreated mice (Fig. 1, E and F) . Amyloid plaque area (Fig. 1G ) and plaque numbers (Fig. 1H ), in the cortex and hippocampus of seven animals per group were quantified and revealed no significant differences between groups in these measures.
Pieces of tissue from corresponding hemibrains were homogenized, then subjected to sandwich enzyme-linked immunosorbent assay (ELISA) analysis to assess levels of tris-buffered saline -soluble (s) and formic acid-extractable insoluble (ins) Ab peptides. We observed a medium effect size [Cohen's d (7)] for soluble and insoluble Ab 40 and soluble Ab 42 , and a small effect size for insoluble Ab 42 between vehicle and Targretin treatment groups (Fig. 1I) . Finally, Western blot analysis using antibodies to ABCA1 revealed an~2.32-fold increase in ABCA1 levels in the brains of Targretin-treated animals compared with the vehicle cohort (Fig. 1 , J and K) (*P < 0.001), thus establishing engagement of an RXR target in the brain.
We then treated cohorts of 3-to 4-month-old male 5XFAD mice [line 6799 (8) ] that exhibit robust amyloid deposition by 2 to 2.5 months of age with Targretin or vehicle, as above. The brains of 11 male mice per treatment group were analyzed; fig. 2 , A and B, shows representative 3D6-labeled sections from individual animals treated with vehicle or Targretin, respectively. Amyloid plaque area (Fig. 2C ) and plaque numbers (Fig. 2D ) in the cortex and hippocampus were quantified and revealed no significant differences between vehicle or Targretin groups in these measures. Sandwich ELISA assays revealed that in contrast to a small effect size for insoluble Ab 40 and insoluble Ab 42 , we observed a very large effect size for soluble Ab 40 and a medium effect size for soluble Ab 42 (Fig. 2E) . The significant reduction in levels of soluble Ab 40 (*P = 0.008; Cohen's d: 1.25) in brains of Targretin-treated mice might be a reflection of the reported rapid reduction of interstitial fluid (ISF) Ab by this compound (2) . Finally, we established target engagement by demonstrating ã 2.46-fold elevation in ABCA1 levels in the brains of Targretin-treated animals compared with the vehicle cohort (Fig. 2, F and G) (*P = 0.004).
Concerned by the fact that the vehicle used for the aforementioned studies differed from that used by Cramer et al. (2), we orally treated cohorts of 9-month-old male APPPS1-21 mice (4) with 100 mg/kg Targretin suspended in H 2 O or with H 2 O as the vehicle. This strain was also used by Cramer and colleagues (2) and exhibits robust Ab deposition by 8 months of age. Sections were stained with a polyclonal antibody to Ab [CN3 (9)] and Fig. 2 , H and I, are representative Ab-labeled sections from individual animals treated with H 2 O or Targretin, respectively. Analysis of amyloid plaque load in four male mice per group failed to reveal a significant difference between H 2 O or Targretin-treated animals (Fig. 2J) , and Meso Scale Discovery (MSD) analysis using the human 6E10 Ab triplex assay revealed a medium effect size for soluble Ab species and a small effect size for insoluble Ab species (Fig. 2K) . Finally, we demonstrated an~1.5-fold elevation in ABCA1 levels in the brains of Targretin-treated animals compared with the vehicle cohort (Fig. 2, L and M (*P = 0.04), thus establishing engagement of an RXR target in the brain.
In summary, although our studies have not examined the rapid effects of bexarotene on ISF Ab levels or behavior, we have failed to support earlier findings by Cramer et al. (2) that Targretin is efficacious in reducing plaque burden in transgenic mouse models of cerebral Ab deposition. 
